GSE114013 GSE114014 itraconazole 0 v 4 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE114013_GSE114014_itraconazole_0_v_4_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE114013_GSE114014_itraconazole_0_v_4_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE114013_GSE114014_itraconazole_0_v_4_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE114013_GSE114014_itraconazole_0_v_4_human_up.

Results found

Linked to

 

Label

Description

 

Gene

GNAS complex locus

Gene

aldo-keto reductase family 1 member C3

Gene

heme oxygenase 1

Gene

tumor associated calcium signal transducer 2

Gene

aldo-keto reductase family 1 member C2

Gene

transmembrane 4 L six family member 1

Gene

aldo-keto reductase family 1 member B10

Gene

activated leukocyte cell adhesion molecule

Gene

adipogenesis regulatory factor

Gene

CD9 molecule

  • Gene

    GNAS complex locus


  • Gene

    aldo-keto reductase family 1 member C3


  • Gene

    heme oxygenase 1


  • Gene

    tumor associated calcium signal transducer 2


  • Gene

    aldo-keto reductase family 1 member C2


  • Gene

    transmembrane 4 L six family member 1


  • Gene

    aldo-keto reductase family 1 member B10


  • Gene

    activated leukocyte cell adhesion molecule


  • Gene

    adipogenesis regulatory factor


  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.